Amring Pharms Drug Patent Portfolio
Amring Pharms owns 1 orange book drug protected by 8 US patents Given below is the list of Amring Pharms's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7947739 | Tranexamic acid formulations | 04 Mar, 2025 | Active |
| US8022106 | Tranexamic acid formulations | 04 Mar, 2025 | Active |
| US8273795 | Tranexamic acid formulations | 04 Mar, 2025 | Active |
| US8487005 | Tranexamic acid formulations | 04 Mar, 2025 | Active |
| US8791160 | Tranexamic acid formulations | 04 Mar, 2025 | Active |
| US8809394 | Tranexamic acid formulations | 04 Mar, 2025 | Active |
| US8957113 | Tranexamic acid formulations | 04 Mar, 2025 | Active |
| US9060939 | Tranexamic acid formulations | 04 Mar, 2025 | Active |
Latest Legal Activities on Amring Pharms's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Amring Pharms.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 17 Nov, 2023 | US8273795 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 04 Nov, 2022 | US8022106 (Litigated) |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8022106 (Litigated) |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8273795 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8809394 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8791160 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US9060939 |
|
Correspondence Address Change
Critical
| 18 Oct, 2022 | US8487005 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 16 Aug, 2022 | US9060939 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 16 Aug, 2022 | US7947739 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jan, 2022 | US8791160 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 06 Jan, 2022 | US8809394 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 05 Jan, 2021 | US8487005 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 19 Mar, 2020 | US8273795 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Mar, 2019 | US8022106 (Litigated) |
Amring Pharms's Family Patents
Amring Pharms drugs have patent protection in a total of 2 countries. It has a significant patent presence in the US with 82.6% of its patents being US patents. Click
below to unlock the full patent family tree.
Amring Pharms Drug List
Given below is the complete list of Amring Pharms's drugs and the patents protecting them.
1. Lysteda
Lysteda is protected by 8 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US7947739 | Tranexamic acid formulations |
04 Mar, 2025
(4 months from now)
| Active |
| US8022106 | Tranexamic acid formulations |
04 Mar, 2025
(4 months from now)
| Active |
| US8273795 | Tranexamic acid formulations |
04 Mar, 2025
(4 months from now)
| Active |
| US8487005 | Tranexamic acid formulations |
04 Mar, 2025
(4 months from now)
| Active |
| US8791160 | Tranexamic acid formulations |
04 Mar, 2025
(4 months from now)
| Active |
| US8809394 | Tranexamic acid formulations |
04 Mar, 2025
(4 months from now)
| Active |
| US8957113 | Tranexamic acid formulations |
04 Mar, 2025
(4 months from now)
| Active |
| US9060939 | Tranexamic acid formulations |
04 Mar, 2025
(4 months from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Lysteda's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List